Investor Type | Firm |
Type of Fund | Venture Capital Fund |
Industries | BioTech • HealthTech (& Fitness) • Medical Devices (& Hospital Services) |
Stages | Early Stage |
Investing | United States • India • China • Singapore • Taiwan • Asia • Indonesia |
Investment Range | $500,000 - $3,000,000 |
Assets Under Management | $2,000,000,000 |
RiverVest Venture Partners is a venture capital firm headquartered in Suite 5620 China World Trade Center Tower III, No. 1 Jianguomenwai Street, Chaoyang District, Beijing, China, with additional offices in St. Louis, Missouri, San Diego, California, and Cleveland, Ohio. With a clear focus on the life sciences sector, RiverVest applies a combination of science, strategy, and innovation to improve the lives of patients and support entrepreneurs in the biopharma and medical device industries. Since its inception in 2000, RiverVest has established a robust portfolio, demonstrating their expertise in early-stage equity investments with a minimum investment of $500,000 and a maximum of $3,000,000. The firm specializes in identifying and investing in promising biopharmaceutical and medical device companies that address significant unmet medical needs. RiverVest manages assets totaling approximately $2 billion and strives to earn the trust of investors while fostering an environment where scientific advancements thrive. The fund has successfully seen the development of 30 commercial products currently treating patients, a testament to its effective investment approach and support of breakthrough therapies. With dedicated funds such as RiverVest Funds I, II, III, Fund IV, and the Archer Seed Fund, the firm has become a prominent player in driving innovation in health-related sectors, particularly BioTech, HealthTech (& Fitness), and Medical Devices (& Hospital Services). RiverVest's website showcases their involvement in advancing medical science, featuring case studies, news of their portfolio companies, like Atalanta Therapeutics, Bluejay Therapeutics, and Alleviant Medical, receiving significant funding and accolades, and contributions to the scientific community through an expanded Scientific Advisory Board.